Denosumab for the treatment of bone metastases in breast cancer: Evidence and opinion

Therapeutic Advances in Medical Oncology

Volumn 3, Issue 5, 2011, Pages 233-243

  Steger, Guenther G ^a   Bartsch, Rupert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

bisphosphonates; bone metastases; cancer treatment induced bone loss; denosumab; osteoporosis; receptor activator of nuclear factor kappaB

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; JAW OSTEONECROSIS; MEDICAL SOCIETY; ONCOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 80054869205     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011412656     Document Type: Review

References (64)

1. American Cancer Society. (2009) Facts and figures. [http://www.cancer.org/docroot/STT/STT_0.asp; last accessed 6 February 2011].
2. Amir E. Ocaña A. Seruga B. Josse R. Clemons M. (2010) Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss. Nat Rev Clin Oncol 7: 187–188.
3. Anastasilakis A.D. Toulis K.A. Goulis D.G. Polyzos S.A. Delaroudis S. Giomisi A. et al (2009) Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: A systematic review and a meta-analysis. Horm Metab Res 41: 721–729.
4. Baron R. Ferrari S. Russell C. (2011) Denosumab and bisphosphonates: Different mechanisms of action and effect. Bone 48: 677–692.
5. Bartsch R. Steger G.G. (2009) Role of denosumab in breast cancer. Expert Opin Biol Ther 9: 1225–1233.
6. Bekker P.J. Holloway D. Nakanishi A. Arrighi M. Leese P.T. Dunstan C.R. (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16: 348–360.
7. Bekker P.J. Holloway D.L. Rasmussen A.S. Murphy R. Martin S.W. Leese P.T. et al (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 1059–1966.
8. Beleut M. Rajaram R.D. Caikovski M. Ayyanan A. Germano D. Choi Y. et al (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A 107: 2989–2994.
9. Bendre M.S. Margulies A.G. Walser B. Akel N.S. Bhattacharrya S. Skinner R.A. et al (2005) Tumour derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappa B ligand pathway. Cancer Res 65: 11001–11009.
10. Body J.J. Facon T. Coleman R.E. Lipton A. Geurs F. Fan M. et al (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12: 1221–1228.
11. Body J.J. Greipp P. Coleman R.E. Facon T. Geurs F. Fermand J.P. et al (2003) A phase I study of AMGN-0007 a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97: 887–892.
12. Brown, J.E., Barrios, C.H., Diel, I.J., Facon, T., Fizazi, K., Ibrahim, T. et al. (2010) Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma. In: 10th International Conference on Cancer-induced Bone Disease, OC-15, Sheffield 22-25 September 2010.
13. Brown J.E. Thomson C.S. Ellis S.P. Gutcher S.A. Purohit O.P. Coleman R.E. (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89: 2031–2037.
14. Brown J.M. Corey E. Lee Z.D. True L.D. Yun T.J. Tondravi M. et al (2001) Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 57: 611–616.
15. Brufsky A.M. Bossermann L.D. Caradonna R.R. Haley B.B. Jones C.M. Moore H.C. et al (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36 months follow-up results. Clin Breast Cancer 9: 77–85.
16. Cartsos V.M. Zhu S. Zavras A.I. (2008) Bisphosphonate use and the risk of adverse jaw outcomes. J Am Dent Assoc 139: 23–30.
17. Chikatsu N. Takeuchi Y. Tamura Y. Fukumoto S. Yano K. Tsuda E. et al (2000) Interactions between cancer and bone marrow cells induCEOsteoclast differentiation factor expression and osteoclast-like cell formation. in vitro. Biochem Biophys Res Comm 267: 632–637.
18. Coleman R. Bundred N. de Boer R. Llombarto A. Campbell I. Neven P. et al (2009) Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Cancer Res 69: 733s–733s.
19. Coleman R.E. (2001) Metastatic bone disease: Clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev 27: 165–176.
20. Coleman R.E. Thorpe H.C. Cameron D. Dodwell D. Burkinshaw R. Keane M. et al (2010) Adjuvant treatment with zoledronic acid in stage II / III breast cancer. The AZURE Trial (BIG 01/04). In: 33rd Annual San Antonio Breast Cancer Symposium (SABCS) Abstract S4–S5.
21. Cummings S.R. San Martin J. McClung M.R. Siris E.S. Eastell R. Reid I.R. et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756–765.
22. Eastell R. Hannon R.A. Cuzick J. Dowsett M. Clack G. Adams J.E. (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21: 1215–1223.
23. Eidtmann H. de Boer R. Bundred N. Llombart-Cussac A. Davidson N. Neven P. et al (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol doi: 10.1093/annonc/mdq217 [Epub ahead of print].
24. Ellis G.K. Bone H.G. Chlebowski R. Paul D. Spadafora S. Fan M. et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26: 4875–4882.
25. Farrugia A.N. Atkins G.J. To L.B. Pan B. Horvath N. Kostakis P. et al (2003) Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63: 5438–5445.
26. Fizazi K. Carducci M. Smith M. Damião R. Brown J. Karsh L. et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 377: 813–822.
27. Fizazi K. Lipton A. Mariette X. Body J.J. Rahim Y. Gralow J.R. et al (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27: 1564–1571.
28. Frith J.C. Mönkkönen J. Auriola S. Mönkkönen H. Rogers M.J. (2001) The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44: 2201–2210.
29. Geusens P. (2009) Emerging treatments for postmenopausal osteoporosis – focus on denosumab. Clin Interv Aging 4: 241–250.
30. Giuliano N. Colla S. Rizzoli V. (2004) Update on the pathogenesis of osteolysis in multiple myeloma patients. Acta Biomed 75: 143–152.
31. Gnant M.F. Mlineritsch B. Luschin-Ebengreuth G. Grampp S. Kaessmann H. Schmid M. et al (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25: 820–828.
32. Gnant M. Mlineritsch B. Schippinger W. Luschin-Ebengreuth G. Pöstlberger S. Menzel C. et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679–691.
33. Hauschka P.V. Mavrakos A.E. Iafrati M.D. Doleman S.E. Klagsbrun M. (1986) Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-sepharose. J Biol Chem 261: 12665–12674.
34. Henry D.H. Costa L. Goldwasser F. Hirsh V. Hungria V. Prausova J. et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29: 1125–1132.
35. Hines S.L. Mincey B.A. Sloan J.A. Thomas S.P. Chottiner E. Loprinzi C.L. et al (2009) Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 27: 1047–1053.
36. Howell A. Cuzick J. Baum M. Buzdar A. Dowsett M. Forbes J.F. et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 yearś adjuvant treatment for breast cancer. Lancet 365: 60–62.
37. Kanis J.A. Delmas P. Burckhardt P. Cooper C. Torgerson D. (2007) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7: 390–406.
38. Kitazawa S. Kitazawa R. (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198: 228–236.
39. Kostenuik P.J. Singh G. Suyama K.L. Orr F.W. (1992) A quantitative model for spontaneous bone metastasis: Evidence for a mitogenic effect of bone on Walker 256 cancer cells. Clin Exp Metastasis 10: 403–410.
40. Kretzschmar A. Wiege T. Al-Batran S.E. Hinrichs H.F. Kindler M. Steck T. et al (2007) Rapid and sustained influence of intravenous zoledronic acid on course of pain and analgesics consumption in patients with cancer with bone metastases: A multicenter open-label study over 1 year. Support Cancer Ther 4: 203–210.
41. Kudo O. Sabokbar A. Pockok A. Itonaga I. Fujikawa Y. Athanasou N.A. (2003) Interleukin-6 and Interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32: 1–7.
42. Lipton A. Steger G.G. Figueroa J. Alvarado C. Solal-Celigny P. Body J.J. et al (2007) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25: 4431–4437.
43. Luckman S.P. Hughes D.E. Coxon F.P. Graham R. Russell G. Rogers M.J. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581–589.
44. Miller R.E. Branstetter D. Armstrong A. Kennedy B. Jones J. Cowan L. et al (2007) Receptor activator of NF-κB ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune response to influenza infection. J Immunol 179: 266–274.
45. Mundy G.R. (2001) Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584–593.
46. Neville-Webbe H.L. Coleman R.E. (2010) Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 46: 1211–1222.
47. Perez E.A. Josse R.G. Pritchard K.I. Ingle J.N. Martino S. Findlay B.P. et al (2006) Effect of letrozol versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A comparison study to NCIC CTC MA.17. J Clin Oncol 24: 3629–3635.
48. Rodan G.A. Martin T.J. (1981) Role of osteoblasts in hormonal control of bone resorption: A hypothesis. Calcif Tissue Int 33: 349–351.
49. Roodman G.D. (2004) Mechanisms of bone metastases. N Engl J Med 350: 1655–1664.
50. Ross J.R. Saunders Y. Edmonds P.M. Patel S. Broadley K.E. Johnston S.R. (2003) Systematic review of the role of bisphosphonates on skeletal morbidity in metastatic breast cancer. BMJ 327: 469–474.
51. Schramek D. Leibbrandt A. Sigl V. Kenner L. Pospisilik J.A. Lee H.J. et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98–102.
52. Smith M.R. Egerdie B. Hernández Toriz N. Feldman R. Tammela T.L. Saad F. et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361: 7445–7455.
53. Stolina M. Guo J. Faggioni R. Brown H. Senaldi G. (2003) Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin Immunol 109: 347–354.
54. Stopeck A. Fallowfield L. Patrick D. Cleeland C.S. de Boer R.H. Steger G.G. et al (2010 a) Effect of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial. J Clin Oncol 28 (15): Abstract 1024.
55. Stopeck A.T. Lipton A. Body J.J. Steger G.G. Tonkin K. de Boer R.H. et al (2010 b) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 28: 5132–5139.
56. Stopeck A. Martin M. Ritchie D. Body J.J. Paterson A. Viniegra M. et al (2010 c) Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: Results from the extended blinded treatment phase. Cancer Res 2010: P6-14-01–P6-14-01.
57. Thomas R.J. Guise T.A. Yin J.J. Elliott J. Horwood N.J. Martin T.J. et al (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451–4458.
58. Thürlimann B. Keshaviah A. Coates A.S. Mouridsen H. Mauriac L. Forbes J.F. et al (2005) Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2727–2757.
59. Valachis A. Polyzos N.P. Gergoulias V. Mavroudis D. Mauri D. (2010) Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis. Gynecol Oncol 117: 139–145.
60. van den Wyngaert T. Wouters K. Huizing M.T. Vermorken J.B. (2011) RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): Non bis in idem? Support Care Cancer doi: 10.1007/s00520-010-1061-0 [Epub ahead of print].
61. van Poznak C. Hannon R.A. Mackey J.R. Campone M. Apffelstaedt J.P. Clack G. et al (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial. J Clin Oncol 28: 967–975.
62. Vega D. Maalouf N.M. Sakhaee K. (2007) The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: Clinical implications. J Clin Endocrinol Metab 92: 4514–4521.
63. Wong B.R., Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272: 25190–25194.
64. Yin J.J. Pollock C.B. Kelly K. (2005) Mechanisms of cancer metastasis to the bone. Cell Res 15: 57–62.